Clinical and instrumental (ECG, PCG, ultrasonic cardiography and polycardiography) examination of cardiac activity in 98 breast cancer patients treated at the Center after Cooper established the cardiotoxic effect of 5-fluorouracil, vincristine, methotrexate, cyclophosphamide and corticosteroids. 46% of them suffered pain in the region of the heart, tachycardia, extrasystole, atrial flutter and deranged conduction function. Congestive heart failure was observed in 7% only. In 24%, myocardial lesions could be detected by instrumental means only. They were identified on the basis of an increase in terminal diastole and systole volume and mass of the myocardium matched by a decrease in stroke volume, PCG amplitude, % delta S and VCF. Cardiac disorders did not persist and were hardly detectable during medication course intervals or one-two months after treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Double Encapsulation of Resveratrol and Doxorubicin in Composite Nanogel-An Opportunity to Reduce Cardio- and Neurotoxicity of Doxorubicin.
Gels
October 2024
Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.
The simultaneous encapsulation of drugs into nanosized delivery systems could be beneficial for cancer therapies since it could alleviate adverse reactions as well as provide synergistic effects. However, the encapsulation of hydrophobic drugs into hydrophilic nanoparticles, such as nanogels, could be challenging. Therefore, innovative technological approaches are needed.
View Article and Find Full Text PDFLeft and right ventricular global longitudinal strain assessment together with biomarker evaluation may have a predictive and prognostic role in patients qualified for hematopoietic stem cell transplantation due to hematopoietic and lymphoid malignancies - a pilot study description.
Cardiooncology
February 2024
Department of Cardio-Oncology, Chair of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland.
The hematopoietic stem cell transplantation (HSCT) procedure is considered a cardiovascular burden. This is due to the potentially cardiotoxic cytostatic agents used before and the risks associated with peri-transplant procedures. We designed a pilot study to determine the clinical utility of the new ST2 marker; furthermore, we routinely assessed cardiac parameters in HSCT recipients.
View Article and Find Full Text PDFAnthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Eur J Cancer
May 2023
The University of Texas, MD Anderson Cancer Center Houston, TX, USA. Electronic address:
Anthracyclines have contributed significantly to remarkable improvements in overall survival and are regarded as the most effective cytostatic drug for cancer treatment in various malignancies. However, anthracyclines are a significant cause of acute and chronic cardiotoxicity in cancer patients, and long-term cardiotoxicity can lead to death in about one-third of patients. Several molecular pathways have been implicated in the development of anthracycline-induced cardiotoxicity, although the underlying mechanisms of some molecular pathways are not fully elucidated.
View Article and Find Full Text PDFSIRT1 activation and its effect on intercalated disc proteins as a way to reduce doxorubicin cardiotoxicity.
Front Pharmacol
November 2022
Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, Saint Petersburg, Russia.
According to the World Health Organization, the neoplasm is one of the main reasons for morbidity and mortality worldwide. At the same time, application of cytostatic drugs like an independent type of cancer treatment and in combination with surgical methods, is often associated with the development of cardiovascular complications both in the early and in the delayed period of treatment. Doxorubicin (DOX) is the most commonly used cytotoxic anthracycline antibiotic.
View Article and Find Full Text PDFBeyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.
Adv Pharmacol
June 2022
Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Cancer patients are at an increased risk of cardiovascular events. Both old-generation cytostatics/cytotoxics and new-generation "targeted" drugs can in fact damage cardiomyocytes, endothelial cells of veins and arteries, specialized cells of the conduction system, pericardium, and valves. A new discipline, cardio-oncology, has therefore developed with the aim of protecting cancer patients from cardiovascular events, while also providing them with the best possible oncologic treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!